Resistance pathways relevant to insulin-like growth factor-1 receptor-targeted therapy

Current Opinion in Investigational Drugs

Volumn 10, Issue 10, 2009, Pages 1032-1040

  Hendrickson, A W ^a   Haluska, P ^a  

^a MAYO CLINIC   (United States)

Author keywords

Epithelial to mesenchymal transition; ErbB receptor; Hsp90; IGF 1; IGF 2; Insulin receptor; mAb inhibitor; Tyrosine kinase inhibitor

Indexed keywords

AC 480; ADW 742; BENZIMIDAZOLE; BINDING PROTEIN; BMS 536924; BMS 754807; CARBOPLATIN; CP 751871; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; HEAT SHOCK PROTEIN 90; INSULIN RECEPTOR; MK 0646; NVP AEW 541; PACLITAXEL; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; SOMATOMEDIN C; SOMATOMEDIN RECEPTOR; TANESPIMYCIN; UNCLASSIFIED DRUG;

CANCER COMBINATION CHEMOTHERAPY; DRUG STRUCTURE; DRUG TARGETING; HUMAN; LUNG NON SMALL CELL CANCER; MESENCHYME; NONHUMAN; PHENOTYPE; PROTEIN EXPRESSION; REVIEW;

ANIMALS; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; DRUG DELIVERY SYSTEMS; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; DRUG RESISTANCE, NEOPLASM; HUMANS; NEOPLASMS; RECEPTOR, IGF TYPE 1; SIGNAL TRANSDUCTION;

EID: 70349754556     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (56)

1. Zwike E, Bange J, Ullrich A: Receptor tyrosine kinase signaling as a target for cancer intervention strategies. Endocr Relat Cancer (2001) 8(3):161-173. (Pubitemid 32947638)
2. Chitnis MM, Yuen JS, Protheroe AS, Pollak M, Macaulay VM: The type 1 insulin-like growth factor receptor pathway. Clin Cancer Res (2008) 14(20):6364-6370.
3. Kurmasheva RT, Houghton PJ: IGF-I mediated survival pathways in normal and malignant cells. Biochem Biophys Acta (2006) 1766(1):1-22.
4. Pollak MN, Schernhammer ES, Hankinson SE: Insulin-like growth factors and neoplasia. Nat Rev Cancer (2004) 4(7):505-518. • Outstanding review addressing the role of IGF in the development of human cancer.
5. Yee D: Targeting insulin-like growth factor pathways. Br J Cancer (2006) 94(4):465-468. • Reviews the strategies and feasibility of targeting the IGF signaling system as a therapeutic strategy for cancer.
6. Pandini G, Frasca F, Mineo R, Sciacca L, Vigneri R, Belfiore A: Insulin/insulin-like growth factor I hybrid receptors have different biological characteristics depending on the insulin receptor isoform involved. J Biol Chem (2002) 42(18):39684-39695. •• A landmark study demonstrating that the IGF-1R/IR HRs had varying affinities for the IGF ligands, and that the IGF-1R and IR receptor pairs had non-preferential pairing partners. (Pubitemid 35190951)
7. Vella V, Pandini G, Sciacca L, Mineo R, Vigneri R, Pezzino V, Belfiore A: A novel autocrine loop involving IGF-II and the insulin receptor isoform-A stimulates growth of thyroid cancer. Clin Endocrinol Metab (2002) 87(1):245-254. • Presents data supporting IGF-2 activation of IR-A as a growth stimulatory pathway of IGF signaling. Demonstrated that IGF signaling could occur through an IGF-1R-independent mechanism.
8. Weroha SJ, Haluska P: IGF-1 receptor inhibitors in clinical trials - Early lessons. J Mammary Gland Biol Neoplasia (2008) 13(4):471-483. • Reviews data on the individual compounds targeting the IGF system that were in clinical development, including data on tolerability and side effects.
9. Haluska P, Shaw HM, Batzel GN, Yin D, Molina JR, Molife LR, Yap TA, Roberts ML, Sharma A, Gualberto A, Adjei AA et al: Phase I dose escalation study of the anti insulin-like growth factor-I receptor monoclonal antibody CP-751,871 in patients with refractory solid tumors. Clin Cancer Res (2007) 13(19):5834-5840. • Presents data from the first phase I, pharmacokinetic clinical trial assessing a compound targeting IGF signaling. (Pubitemid 47583908)
10. Hartog H, Wesseling J, Boezen HM, van der Graaf WT: The insulin-like growth factor 1 receptor in cancer: Old focus, new future. Eur J Cancer (2007) 43(13):1895-1904. • Provides a list of the studies in which the percentage of different tumors that express the IGF-1R has been documented, thus providing a good assessment of the frequency of IGF-1R expression in cancer. (Pubitemid 47284866)
11. Frasca F, Pandini G, Sciacca L, Pezzino V, Squatrito S, Belfiore A, Vigneri R: The role of insulin receptors and IGF-1 receptors in cancer and other diseases. Arch Physiol Biochem (2008) 114(1): 23-37. • An outstanding review that puts into context the role of IR signaling in terms of IGF signaling and IGF-targeted therapies. (Pubitemid 351998752)
12. Grothey A, Voigt W, Schöber C, Müller T, Dempke W, Schmoll HJ: The role of insulin-like growth factor I and its receptor in cell growth, transformation, apoptosis, and chemoresistance in solid tumors. J Cancer Res Clin Oncol (1999) 125(3-4):166-173. (Pubitemid 29172507)
13. Macaulay VM: Insulin-like growth factors and cancer. Br J Cancer (1992) 65(3):311-320.
14. LeRoith D, Roberts CT Jr: 14. The insulin-like growth factor system and cancer. Cancer Lett (2003) 195(2):127-137. (Pubitemid 36588961)
15. Miller BS, Yee D: 15. Type I insulin-like growth factor receptor as a therapeutic target in cancer. Cancer Res (2005) 65(22):10123-10127. (Pubitemid 41743697)
16. Sachdev D, Yee D: 16. Disrupting insulin-like growth factor signaling as a potential for cancer therapy. Mol Cancer Ther (2007) 6(1):1-12. (Pubitemid 46206663)
17. Mohan S, Baylink DJ: 17. Beyond carrier proteins: IGF-binding proteins are multifunctional and act via IGF-dependent and -independent mechanisms. J Endocrinol (2002) 175(1): 19-31.
18. Perks CM, Holly JM: IGF binding proteins (IGFBPs) and regulation of breast cancer biology. J Mammary Gland Biol Neoplasia (2008) 13(4):455-469.
19. Haluska P, Ten Eyck C, Carboni JM, Asmann TW, Saulnier MG, Frennesson, Attar RM, Conover CA, Wittman MD, Gottardis M, Erlichman C: Insulin-like growth factor binding protein-5 is overexpressed in breast cancer cells resistant to IG-1R inhibition. Proceedings from the 15th SPORE Investigators' Workshop, Baltimore, MD, USA (2007).
20. Huang F, Greer A, Hurlburt W, Han X, Hafezi R, Wittenberg GM, Reeves K, Chen J, Robinson D, Li A, Lee FY et al: The mechanisms of differential sensitivity to an insulin-like growth factor-1 receptor inhibitor (BMS-536924) and rationale for combining with EGFR/HER2 inhibitors. Cancer Res (2009) 69(1):161-170.
21. Lacy MQ, Alsina M, Fonseca R, Paccagnella ML, Melvin CL, Yin D, Sharma A, Enriquez Sarano M, Pollak M, Jagannath S, Richardson P et al: Phase I, pharmacokinetic and pharmacodynamic study of the anti-insulin-like growth factor type 1 receptor monoclonal antibody CP-751,871 in patients with multiple myeloma. J Clin Oncology (2008) 26(19):3196-3203.
22. Hidalgo M, Tirado Gomez M, Lewis N, Vuky JL, Taylor G, Hayburn JL, Hsu K, Kosh M, Picozzi VJ: A phase I study of MK-0646, a humanized monoclonal antibody against the insulin-like growth factor receptor type 1 (IGF1R) in advanced solid tumor patients in a q2 wk schedule. J Clin Oncol (2008) 26 (Suppl 15S):3520.
23. Isaacs JS, Xu W, Neckers L: Heat shock protein 90 as a molecular target for cancer therapeutics. Cancer Cell (2003) 3(3):213-217. • Reviews data on targeting Hsp90 as a treatment for human cancers. (Pubitemid 37443877)
24. Neckers L: Hsp 90 inhibitors as novel cancer chemotherapeutic agents. Trends Mol Med (2002) 8(4):S55-S61.
25. Zhang H, Burrows F: Targeting multiple signal transduction pathways through inhibition of Hsp 90. J Mol Med (2004) 82(8):488-499. (Pubitemid 39149859)
26. Gooljarsingh LT, Fernandes C, Yan K, Zhang H, Grooms M, Johanson K, Sinnamon RH, Kirkpatrick RB, Kerrigan J, Lewis T, Arnone M et al: A biochemical rationale for the anticancer effects of Hsp90 inhibitors: Slow, tight binding inhibition by geldanamycin and its analogues. Proc Natl Acad Sci USA (2006) 103(20):7625-7630. (Pubitemid 43752831)
27. Lang SA, Moser C, Gaumann A, Klein D, Glockzin G, Popp FC, Dahlke MH, Piso P, Schlitt HJ, Geissler EK, Stoeltzing O: Targeting heat shock protein 90 in pancreatic cancer impairs insulin-like growth factor-1 receptor signaling, disrupts an interleukin-6/signal-transducer and activator of transcription 3/hypoxia-inducible factor 1α autocrine loop, and reduces orthotopic tumor growth. Clin Cancer Res (2007) 13(21):6459-6468. • Presents in vivo data demonstrating that targeting Hsp90 disrupted IGF-1R signaling.
28. Martins AS, Ordoñez JL, García-Sánchez A, Herrero D, Sevillano V, Osuna D, Mackintosh C, Caballero G, Otero AP, Poremba C, Madoz-Gúrpide J et al: A pivotal role for heat shock protein 90 in Ewing sarcoma resistance to anti-insulin-like growth factor 1 receptor treatment: In vitro and in vivo study. Cancer Res (2008) 68(15):6260-6270. • Presents in vitro and in vivo data supporting a role for Hsp90 in the development of resistance to IGF-targeted treatment.
29. Pandini G, Vigneri R, Constantino A, Frasca F, Ippolito A, Fujita-Yamaguchi Y, Siddle K, Goldfine ID, Belfiore A: Insulin and insulin-like growth factor-I (IGF-I) receptor overexpression in breast cancers leads to insulin/IGF-I hybrid receptor overexpression: Evidence for a second mechanism of IGF-I signaling. Clin Cancer Res (1999) 5(7):1935-1944.
30. Belfiore A: The role of insulin receptor isoforms and hybrid insulin/IGF-1 receptors in human cancer. Curr Pharm Des (2007) 13(7):671-686.
31. Papa V, Gliozzo B, Clark GM, McGuire WL, Moore D, Fujita-Yamaguchi Y, Vigneri R, Goldfine ID, Pezzino V: Insulin-like growth factor-I receptors are overexpressed and predict a low risk in human breast cancer. Cancer Res (1993) 53(16):3736-3740. (Pubitemid 23252035)
32. Frittitta L, Vigneri R, Papa V, Goldfine ID, Grasso G, Trischitta V: Structural and functional studies of insulin receptors in human breast cancer. Breast Cancer Res Treat (1993) 25(1): 73-82. (Pubitemid 23107738)
33. Milazzo G, Giorgino F, Damante G, Sung C, Stampfer MR, Vigneri R, Goldfine ID, Belfiore A: Insulin receptor expression and function in human breast cancer cell lines. Cancer Res (1992) 52(14):3924-3930.
34. Moller DE, Yokota A, Caro JF, Flier JS: Tissue-specific expression of two alternatively spliced insulin receptor mRNAs in man. Mol Endocrinol (1989) 3(8):1263-1269. (Pubitemid 19210437)
35. Denley A, Wallace JC, Cosgrove LJ, Forbes BE: The insulin receptor isoform exon 11- (IR-A) in cancer and other diseases: A review. Horm Metab Res (2003) 35(11-12):778-785. (Pubitemid 38058183)
36. Doepfner KT, Spertini O, Arcaro A: Autocrine insulin-like growth factor-1 signaling promotes growth and survival of human acute myeloid leukemia cells via the phosphoinositide 3-kinase/Akt pathway. Leukemia (2007) 21(9):1921-1930.
37. Hendrickson AEW, Karp JE, Carboni J, Attar RM, Smith BD, Whittman M, Gottardis M, Haluska PJ, Kaufmann SH: Apoptotic and anti-proliferative effects of the dual insulin-like growth factor-1 (IGF-1R)/insulin receptor inhibitor, BMS 536924, in acute myelogenous leukemia. Abstr AACR (2007) 98:Abs 2375.
38. Pandini G, Wurch T, Akla B, Corvaia N, Belfiore A, Goetsch L: Functional responses and in vivo anti-tumour activity of h7C10: A humanized monoclonal antibody with neutralizing activity against insulin-like growth factor-1 (IGF-1) receptor and insulin/IGF-1 hybrid receptors. Eur J Cancer (2007) 43(8):1318-1327.
39. Hou X, Carboni JM, Macedo LF, Harrington SC, Finckenstein F, Brodie A, Gottardis M, Haluska P: Combined estrogen signaling inhibition and IGF-1R/InsR inhibition with BMS-754807 in estrogen-dependent breast cancer model has synergistic antitumor activity in vitro and in vivo. Abstr AACR (2009) 100: Abs 1743
40. Hou X, Harrington SC, Macedo LF, Weroha SJ, Brodie A, Haluska P: Hormonal therapies differentially enhance insulin receptor isoform A and ErbB receptor up-regulation in response to IGF-1R inhibitor MK-0646 in vivo. Abstr AACR (2009) 100: Abs 2812.
41. Jin Q, Esteva FJ: Cross-talk between the ErbB/HER family and the type I insulin-like growth factor receptor signaling pathway in breast cancer. J Mammary Gland Biol Neoplasia (2008) 13(4):485-498.
42. Wang Q, Greene M: Mechanisms of resistance to ErbB-targeted cancer therapeutics. J Clin Invest (2008) 118(7):2389-2392. (Pubitemid 351949768)
43. Nahta R, Yu D, Hung MC, Hortobagyi GN, Esteva FJ: Mechanisms of disease: Understanding resistance to HER2-targeted therapy in human breast cancer. Nature Clin Pract Oncol (2006) 3(5):269-280. (Pubitemid 43731112)
44. Chakravarti A, Loeffler JS, Dyson NJ: Insulin-like growth factor receptor I mediates resistance to anti-epidermal growth factor receptor therapy in primary human glioblastoma cells through continued activation of phosphoinositide 3-kinase signaling. Cancer Res (2002) 62(1):200-207. • One of the earliest reports of crosstalk between the IGF-1R and EGFR signaling pathways.
45. Haluska P, Carboni JM, TenEyck C, Attar RM, Hou X, Yu C, Sagar M, Wong TW, Gottardis MM, Erlichman C: HER receptor signaling confers resistance to the insulin-like growth factor-I receptor inhibitor, BMS-536924. Mol Cancer Ther (2008) 7(9):2589-2598. • Presents data demonstrating that bidirectional crosstalk between the IGF and HER receptors, and that HER receptor expression and activation was sufficient to overcome IGF-1R inhibition.
46. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL: Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science (1987) 235(4785):177-182.
47. Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE Jr, Davidson NE, Tan-Chiu E, Martino S, Paik S, Kaufman PA, Swain SM et al: Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med (2005) 353(16):1673-1684. (Pubitemid 41464706)
48. Lu Y, Zi X, Zhao Y, Mascarenhas D, Pollak M: Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin). J Natl Cancer Inst (2001) 93(24):1852-1857. • One of the earliest studies to demonstrate that IGF-1R expression was sufficient to overcome resistance to HER-2 targeting. (Pubitemid 34048651)
49. Nahta R, Yuan LX, Zhang B, Kobayashi R, Esteva FJ: Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells. Cancer Res (2005) 65(23): 11118-11128. (Pubitemid 41713383)
50. Savagner P: Leaving the neighborhood: Molecular mechanisms involved during epithelial-mesenchymal transition. Bioessays (2001) 23(10):912-923.
51. Vernon AE, LaBonne C: Tumor metastasis: A new twist on epithelial-mesenchymal transitions. Curr Biol (2004) 14(17):R719-R721. (Pubitemid 39290047)
52. Yang J, Weinberg RA: Epithelial-mesenchymal transition: At the crossroads of development and tumor metastasis. Dev Cell (2008) 14(6):818-829. (Pubitemid 351757205)
53. Mauro L, Salerno M, Morelli C, Boterberg T, Bracke ME, Surmacz E: Role of the IGF-I receptor in the regulation of cell-cell adhesion: Implications in cancer development and progression. J Cell Physiol (2002) 194(2):108-116. (Pubitemid 36043625)
54. Kim HJ, Litzenburger BC, Cui X, Delgado DA, Grabiner BC, Lin X, Lewis MT, Gottardis MM, Wong TW, Attar RM, Carboni JM et al: Constitutively active type I insulin-like growth factor receptor causes transformation and xenograft growth of immortalized mammary epithelial cells and is accompanied by an epithelial-to-mesenchymal transition mediated by NF-κB and Snail. Mol Cell Biol (2007) 27(8):3165-3175. • Establishes the role of IGF-1 signaling in cell transformation and the mechanism of EMT. Helps to explain why squamous cell lung cancer tumors were more sensitive to IGF-1R targeting compared with non-squamous NSCLCs.
55. Karp DD, Paz-Ares LG, Novello S, Haluska P, Garland L, Cardenal F, Blakely LJ, Eisenberg PD, Langer CJ, Blumenschein G Jr, Johnson FM et al: Phase II study of the anti-insulin-like growth factor type 1 receptor antibody CP-751,871 in combination with paclitaxel and carboplatin in previously untreated, locally advanced, or metastatic non-small-cell lung cancer. J Clin Oncol (2009) 27(15):2516-2522.
56. Gualberto A, Melvin AL, Dean A, Ang AL, Reynolds J, Lee AV, Terstappen LW, Haluska P, Lipton A, Karp DD: Characterization of NSCLC patients responding to anti-IGF-1R therapy. Abstr ASCO (2008) 44:Abs 8000.